While the Outperform rating suggests that Oppenheimer still sees Apellis Pharmaceuticals as a good investment, the reduction in the price target could imply a tempered expectation for the stock's growth potential in the short term. This might lead to mixed reactions in the market, with some investors seeing the lowered target as a sign of caution, while others may focus on the continued positive outlook.